Objective To observe the clinical efficacy and safety of oral propranolol in the treatment of infantile ocular hemangioma. Methods A prospective study was conducted to analyze the size, color changes and adverse reactions of 66 children with ocular hemangioma treated in pediatric ophthalmic outpatient department from February 2016 to April 2018, and to evaluate the clinical efficacy and safety.Results 83.3% of children in 1 weeks tumors had the color becomes shallow or filling degree of the previous decline, curative effect Ⅰ level 4 cases(6.1%),Ⅱ level 7 cases(10.6%),Ⅲ level 9 cases(13.6%), grade Ⅳ 46 cases(69.7%). The average treatment time was 6.9 months. The effect of the long course group was better than that of the short course group, and the clinical effect of 4~12 months was better than that of the other treatment groups. No obvious side effects were found in 1 case of diarrhea during the treatment. Tumors had rebounded after the drug was stopped in 1 case, again after Ⅳ curative effect.Conclusions Oral propranolol as a first-line treatment for infantile ocular hemangioma is equally safe and effective in the clinic.
Journal of Clinical Ophthalmology